Prostate Cancer: S1216 (Hematology Oncology Associates)

S1216: A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer

Objective

The purpose of this study is to find out what effects (good and/or bad) there are to adding the new investigational drug TAK-700 (also called orteronel) to standard hormone therapy which is used to treat prostate cancer as compared to the standard of hormone therapy alone. The combination of TAK-700 and standard hormone therapy is considered experimental. Patients eligible for this study are those that have prostate cancer that has spread and they are either beginning hormone therapy for the first time or have been on hormone therapy for less than 30 days.

TAK-700 is a pill that works by reducing the levels of testosterone and other male hormones that help prostate cancer grow. TAK-700 acts on the adrenal glands and inside the prostate tumors and slows the amount of male hormones being produced. By lowering the amount of male hormones in the body, TAK-700 is expected to control the growth of prostate cancer.

Click here for more information from the National Cancer Institute.

Principal Investigator(s)
Shobha Chitneni

Clinical Trial Categories

  • Cancer
  • Prostate Cancer
Sponsor(s)
SWOG
Contact
Katy D'Aprile, RN, BSN at 563-355-7733

Location

  • Hematology Oncology Associates of the Quad Cities
    1351 East Kimberly Road
    Suite 100
    Bettendorf, IA 52722

Contact Us

For more information about our research program and IRB, please contact:

Research Support Office
563-421-7955

Email